MedTrace Logo

A Phase 1 Study of CLYM116 in Normal Healthy Volunteers

NCT07248865 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-02-20

No results posted yet for this study

Summary

This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CLYM116 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

CLYM116

CLYM116 to be administered by SC injection

DRUG

Placebo

Placebo solution to be administered at a matching volume by SC injection

Sponsors & Collaborators

  • Climb Bio, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-02
Primary Completion
2026-07-31
Completion
2026-09-30
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07248865 on ClinicalTrials.gov